SolidarMed, Maseru, Lesotho Seboche Hospital, Botha-Bothe, Lesotho SolidarMed, Lucerne, Switzerland Institute of Tropical Medicine, Antwerp, Belgium.
Trop Med Int Health. 2012 Oct;17(10):1245-54. doi: 10.1111/j.1365-3156.2012.03051.x. Epub 2012 Jul 29.
In 2007, Lesotho launched new national antiretroviral treatment (ART) guidelines, prioritising tenofovir and zidovudine over stavudine as a backbone together with lamivudine. We compared the rate of adoption of these new guidelines and substitution of first-line drugs by health centers (HC) and hospitals in two catchment areas in rural Lesotho.
Retrospective cohort analysis. Patients aged ≥16 years were stratified into a HC- and a hospital-group.
Type of backbone at ART-initiation (i), substitutions within first line (ii) and type of backbone among patients retained by December 2010 (iii). A multiple logistic regression model including HC vs. hospital, patient characteristics (sex, age, WHO-stage, baseline CD4-count, concurrent pregnancy, concurrent tuberculosis treatment) and year of ART-start, was used.
Of 3936 adult patients initiated on ART between 2007 and 2010, 1971 started at hospitals and 1965 at HCs. Hospitals were more likely to follow the new guidelines as measured by prescription of backbones without stavudine (Odds-ratio 1.55; 95%CI: 1.32-1.81) and had a higher rate of drug substitutions while on first-line ART (2.39; 1.83-3.13). By December 2010, patients followed at health centres were more likely to still receive stavudine (2.28; 1.83-2.84).
Health centers took longer to adopt the new guidelines and substituted drugs less frequently. Decentralised ART-programmes need close support, supervision and mentoring to absorb new guidelines and to adhere to them.
2007 年,莱索托推出了新的国家抗逆转录病毒治疗(ART)指南,优先选择替诺福韦和齐多夫定作为骨干药物,联合使用拉米夫定,取代司他夫定。我们比较了这两个农村莱索托集水区的卫生中心(HC)和医院采用这些新指南和一线药物替代的情况。
回顾性队列分析。将年龄≥16 岁的患者分为 HC 组和医院组。
ART 起始时的骨干药物类型(i)、一线药物的替代情况(ii)和 2010 年 12 月前保留的患者骨干药物类型(iii)。采用包含 HC 与医院、患者特征(性别、年龄、WHO 分期、基线 CD4 计数、同期妊娠、同期结核病治疗)和 ART 起始年份的多因素逻辑回归模型。
在 2007 年至 2010 年间接受 ART 治疗的 3936 名成年患者中,有 1971 名在医院开始治疗,1965 名在 HC 开始治疗。与 HC 相比,医院更可能遵循新指南,表现为处方不含司他夫定的骨干药物(比值比 1.55;95%CI:1.32-1.81),一线 ART 期间药物替代率更高(2.39;1.83-3.13)。到 2010 年 12 月,在 HC 接受治疗的患者更可能仍在接受司他夫定(2.28;1.83-2.84)。
HC 采用新指南的时间较长,药物替代频率较低。分散的 ART 项目需要密切的支持、监督和指导,以吸收新指南并遵守它们。